摘要
目的:探讨调脾护心方治疗心脾两虚型心房颤动患者的临床疗效。方法:选择60例心脾两虚型房颤患者,随机分为两组,观察组30例,对照组30例,均给予控制心室率西药(琥珀酸美托洛尔片)及抗凝西药(利伐沙班片)治疗;观察组在此基础上加用调脾护心方治疗,两组疗程均为12周,评估两组24 h平均心室率、左房内径(LAD)、左心室射血分数(LVEF)、心房颤动症状疗效和中医证候积分疗效等。结果:治疗后,两组24 h平均心室率均降低(P P P > 0.05);治疗后两组的LVEF值均上升(P P P P Objective: To evaluate the clinical efficacy of Tiaopi Huxin Decoction in treating patients with heart-spleen deficiency type atrial fibrillation (AF). Methods: A total of 60 patients diagnosed with heart-spleen deficiency type AF were randomly assigned to two groups: the observation group (30 patients) and the control group (30 patients). Both groups received standard treatment with rate control medication (Metoprolol Succinate Tablets) and anticoagulant therapy (Rivaroxaban Tablets). In addition to these treatments, the observation group was given Tiaopi Huxin Decoction. The treatment duration for both groups was 12 weeks. Key outcomes, including 24-hour average ventricular rate, left atrial diameter (LAD), left ventricular ejection fraction (LVEF), AF symptom improvement, and Traditional Chinese Medicine (TCM) syndrome scores, were assessed for both groups. Results: Post-treatment, the 24-hour average ventricular rate decreased in both groups (P P P > 0.05). LVEF improved in both groups after treatment (P P P P < 0.05). Conclusion: The Spleen-Regulating and Heart-Protecting Formula has good efficacy in treating atrial fibrillation with heart-spleen deficiency, improving patients’ overall health condition.
出处
《临床医学进展》
2025年第5期1654-1660,共7页
Advances in Clinical Medicine
基金
安徽省中医药领军人才资助项目,编号,中医药发展密[2018]23号。
